Clinical Trial Update: APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) [Phase 1]

View source ↗

Summary

A Phase 1 trial of APR-548 in combination with azacitidine for TP53-mutant myelodysplastic syndromes was terminated. Results were posted in March 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• APR-548
• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Aprea Therapeutics | Conditions: MDS, Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED | Results posted: 2025-03-07